A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban

Kwong, Louis M.; Turpie, Alexander G.G.; Tamayo, Sally; Peacock, W. Frank; Yuan, Zuyi; Sicignano, Nicholas; Hopf, K; Patel, Manesh R.

doi:10.1080/03007995.2017.1351935

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although NOACs display higher efficiency and overcome many of the liabilities of warfarin and heparin, patients with atrial fibrillation still have a 2–3% bleeding risk . Furthermore, patients with severe chronic kidney disease, end-stage renal disease (ESRD) on dialysis, or undergoing total hip and total knee replacement surgery face increased bleeding risks during anticoagulation therapy. − A lower bleeding risk is also urgently required for the elderly and cancer patients. , In a nutshell, one of the most significant barriers to the use of approved anticoagulants is the bleeding risk …”

Section: Introductionmentioning

confidence: 99%

Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives

et al. 2023

View full text Add to dashboard Cite

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be an effective and safe target for anticoagulant discovery with limited or no bleeding. Numerous small-molecule FXIa inhibitors (SMFIs) with various scaffolds have been identified in the early stages of drug discovery. They have served as the foundation for the recent discovery of additional promising SMFIs with improved potency, selectivity, and pharmacokinetic profiles, some of which have entered clinical trials for the treatment of thrombosis. After reviewing the coagulation process and structure of FXIa, this perspective discusses the rational or structure-based design, discovery, structure−activity relationships, and development of SMFIs disclosed in recent years. Strategies for identifying more selective and druggable SMFIs are provided, paving the way for the design and discovery of more useful SMFIs for anticoagulation therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Allogeneic blood transfusion is an independent risk factor affecting the prognosis of THR [ 2 , 3 ]. In addition, massive bleeding will also cause coagulation dysfunction and increase the risk of infection at the surgical site [ 4 ]. Therefore, how to reduce the perioperative blood loss and allogeneic blood transfusion during THR is a huge challenge for clinicians.…”

Section: Introductionmentioning

confidence: 99%

Serum Levels of VWF, t-PA, TNF-α, and ICAM-1 in Patients Receiving Hemocoagulase Combined with Platelet-Rich Plasma during Total Hip Replacement

Huang

Zeng

et al. 2022

Genetics Research

View full text Add to dashboard Cite

Objectives. This study aimed to investigate the effect of hemocoagulase combined with platelet-rich plasma (PRP) in total hip replacement (THR) on reducing bleeding and improving knee joint function in the patients with osteoarthritis. Methods. From February 2018 to February 2020, 80 osteoarthritis patients undergoing THR were included in the study, of which 40 cases were treated with PRP and hemocoagulase (test group) in the joint capsule in THR and the other 40 cases received saline and thrombin in the joint capsule after THR (control group). Postoperative drainage and corresponding functional exercise were performed for the two groups 12 hours after operation. The outcome measures including operation time, soft-tissue release, blood routine, drainage volume, perioperative blood loss, postoperative incision inflammation, deep vein thrombosis (DVT), and range of motion (ROM) of the joint were recorded. Results. The hemoglobin and hematocrit values of the test group on the second postoperative day were significantly higher than those of the control group ( P < 0.05 ). The postoperative drainage volume and perioperative blood loss were significantly lower than those of the control group ( P < 0.05 ). The test group was better than the control group in the ROM of the joint at 7 and 15 days after the operation ( P < 0.05 ). A lower value of prothrombin time and activated partial thromboplastin time was revealed in the test group compared with the control group ( P < 0.05 ). No significant difference in the operation time, intraoperative soft-tissue release, postoperative incision inflammation, incidence of DVT, incidence of deep infection, and ROM at day 90 after THR was found in the two groups ( P > 0.05 ). Conclusions. The application of hemocoagulase combined with PRP in THR can reduce perioperative blood loss, increase wound healing speed and quality, and improve coagulation and immune function. It is a safe and effective method for the patients with knee osteoarthritis who underwent THR.

show abstract

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis

Wei

Zhang

et al. 2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban

Abstract: The incidence of MB in this retrospective analysis is lower than that observed in the clinical trials of rivaroxaban. Whether this is due to lower real-world MB rates or challenges with case-finding algorithms is unclear.

Cited by 4 publications

References 22 publications

Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives

Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives

Serum Levels of VWF, t-PA, TNF-α, and ICAM-1 in Patients Receiving Hemocoagulase Combined with Platelet-Rich Plasma during Total Hip Replacement

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About